Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial

Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial

Background: Mizoribine (MZR) is an immunosuppressive drug used in Japan for treating patients with lupus nephritis and nephrotic syndrome and has been also reportedly effective in patients with immunoglobulin A (IgA) nephropathy. However, to date, few randomized control studies of MZR are performed...

Full description

Bibliographic Details
Main Authors: Keiji Hirai, Susumu Ookawara, Taisuke Kitano, Haruhisa Miyazawa, Kiyonori Ito, Yuichirou Ueda, Yoshio Kaku, Taro Hoshino, Honami Mori, Izumi Yoshida, Kenji Kubota, Yasuyoshi Yamaji, Tetsuro Takeda, Yoshikazu Nakamura, Kaoru Tabei, Yoshiyuki Morishita
Format: Article
Language:English
Published: The Korean Society of Nephrology 2017-06-01
Series:Kidney Research and Clinical Practice
Subjects:
Hematuria
Immunoglobulin A nephropathy
Mizoribine
Online Access:https://doi.org/10.23876/j.krcp.2017.36.2.159

Internet

https://doi.org/10.23876/j.krcp.2017.36.2.159

Similar Items